

Notice of Allowability

Application No.

10/069,799

Examiner

Padmavathi v. Baskar

Applicant(s)

FARN ET AL.

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 7/14/05.
2. ☒ The allowed claim(s) is/are 63, 66 and 72 have beenrenumbered as 1-3 respectively.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☒ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date _____
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date 9/22/9/30
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____

LYNETTE R. F. SMITH
SUPERVISORY PATENT
TECHNOLOGY CENTER

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's request for continued examination filed on 7/14/05 has been entered.

Amendment

2. Applicant's amendment filed on 7/14/05 is acknowledged.

Status of claims

3. Claims 63 and 72 have been amended.

Claims 1-62, 64-65, 67-71 and 73-84 have been canceled.

Claims 63,66 and 72 are under examination as an elected invention.

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Heeja Yoo-Warren 9/22/05 and 9/30/05

The application has been amended as follows:

Claim 72. (Currently amended) A composition for use in raising an immune response in an animal, the composition comprising a substantially purified polypeptide having the amino acid sequence as set out in SEQ ID NO: 5 ~~or a fragment thereof, wherein said fragment is capable of producing an antibody which specifically recognizes the~~

Art unit 1645

poly peptide as set out in SEQ ID NO:5 and optionally a carrier and/or adjuvant.

Claim Rejections - 35 USC 112, first paragraph withdrawn

5. In view of the amendment to the claims 63 and 72, the rejections of claims 63, 66 and 72 under 35 U.S.C. 112, first paragraph written description and enablement are withdrawn.

Claim Rejections – 35 U.S.C. 102 withdrawn

6. In view of the amendment to the claims 63 and 72, the rejection of claims 63, 66 and 72 under 35 U.S.C. 102(e) as being anticipated by Campos et al U.S. Patent: 6,096,320 is withdrawn.

7. In view of the amendment to the claims 63 and 72, the rejection of claims 63, 66 and 72, Billson, F. M. et al. (1994) FEMS Microbiology 124:69-73 is withdrawn.

8. *Moraxella bovis*, a Gram-negative coccobacillus causes Infectious bovine keratoconjunctivitis (IBK), an economically an important disease of cattle commonly known as pinkeye, IBK is a highly contagious ocular infection, which may range from mild conjunctivitis to severe ulceration, corneal perforation and blindness. The claimed invention is drawn to a novel *Moraxella bovis* isolated polypeptide (recombinant) comprising the amino acid sequence SEQ.ID.NO: 5, referred as haemolysin polypeptide and appears to be useful as a candidate vaccine antigen.

9. Claims 63, 66 and 72 are allowed and have been renumbered as 1-3 respectively.

Conclusion

10. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile

Art unit 1645

must conform to the notice published in the Official Gazette, 1096 OG 30, November 15, 1989.

The Right Fax number is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PMR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PMR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PMR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.



Padma Baskar Ph.D.

Art unit 1645

1-62. (Canceled)

63. An isolated polypeptide comprising the amino acid sequence as set out in SEQ ID NO: 5.

64-65. (Canceled)

66. The polypeptide, as claimed in claim 63, having haemolysin activity.

67-71. (Canceled)

72. (Currently amended) A composition for use in raising an immune response in an animal, the composition comprising a substantially purified polypeptide having the amino acid sequence as set out in SEQ ID NO: 5 and optionally a carrier and/or adjuvant.

73-84. (Canceled)